sugar
Conditions
Interventions
The intervention of this study is the DLAM-approach for T2D patients. First the
*360 degree* diagnosis is performed based on health markers and questionnaires
to map the largest physical and/or ment
Sponsors
TNO
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The participants will be recruited from the T2D patient population of healthcare partnership Stevenshof. Four GPA*s work for healthcare partnership Stevenshof. Each GPA will select two T2D patients in each of the two study phases. These patients should meet one of the following requirements: - Patient is newly diagnosed with T2D - Patient is about to start Metformin - Patient is about to start with a second oral drug (like SU-derivates) - Patient is about to start with an injectable drug (Insulin or GLP-1);Besides that, the patients should meet the following inclusion criteria: - Aged between 30-80 - Have a BMI between 25-35 - Willing and able to sign the informed consent form - Able to fill in the 360-degree questionnaire which is in Dutch - Able to work with computers (e.g. for filling in digital questionnaires)
Exclusion criteria
Exclusion criteria: A candidate who meets any of the following criteria will be excluded from participation in this study: - Dialysis patients - Possible limiting personal circumstances (e.g. unemployed, illness in the family, dept restructuring) - Patients under treatment of a psychiatrist - Incapacitated patients - Patients in a palliative phase
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes of this study are process variables related to the organizational and financial feasibility of implementation within primary care: time of primary caregivers, costs of medication and facilities and benefits for patients by lower health care use on the longer term. Relevant questions are: - How much extra time will it take for a primary care caregiver to execute the DLAM-programme? - How much extra time and costs are involved as compared to regular care (e.g. time of care professionals, facilities for extra blood analysis)? - Do the benefits offset the extra time and costs of the DLAM-treatment programme identified by primary care professionals, patients with T2D and health insurers? Besides, experiences of care professionals and patients will be assessed, including: - Conditions for implementation of the DLAM-treatment in daily practice - Bottlenecks and attention points - Advantages, disadvantages and suggestions for improvements | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes are related to (change in) health status of participants which will mainly be evaluated in a qualitative fashion. First, changes in diabetes related markers such as HbA1c, glucose and insulin will be evaluated. Several indices can be derived from an OGGT and can indicate organ-specific effects of a distorted glucose tolerance. With these indices several subtypes of diabetes can be distinguished. Three different indices are used in the stratification of T2D patients: - Disposition Index (DI): a measure for beta-cell function and insulin production capacity. - Hepatic fasting (HG) index: a measure for the insulin resistance in the liver. - Muscle insulin resistance index: a measure for the insulin resistance in the muscles. Besides that, BMI, weight, hip circumference, waist circumference and medication use will be evaluated. Physical aspects will be assessed during the 360-degree diagnosis at baseline and after the intervention. Examples are subjective health, mood, stress, diabetes related worries and pain. | — |
Countries
Netherlands
Outcome results
None listed